WS
ITRM

Wedbush Securities’s Iterum Therapeutics ITRM Stock Holding History

Wedbush Securities’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-791
Closed -$12K – 925
2020
Q3 		$12K Buy
+791
New +$10.6K ﹤0.01% 925

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
SSG
Summit Securities Group New York $1.05B AUM 36.17% 1-Year Est. Return

Wedbush Securities's ITRM Position: Q4 2020 in Review

Wedbush Securities sold out of Iterum Therapeutics (ITRM) in Q4 2020, closing a stake of 791 shares — an estimated $12K sold.

Wedbush Securities first reported a position in ITRM in Q3 2020 and held it in 1 quarter. The position peaked at $12K in Q3 2020. 19 funds tracked by Wall St. Rank hold ITRM as of Q4 2020.

  • Wedbush Securities reported no remaining Iterum Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 791 Iterum Therapeutics shares in Q4 2020, an estimated $12K.
  • Wedbush Securities first reported a position in Iterum Therapeutics in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Iterum Therapeutics position peaked at $12K in Q3 2020.
  • 19 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.